

Drug Class Review Monograph – GPI Class 04 – Tetracyclines

Review Time Frame: 02/2016 – 04/2017

Previous Class Review: 05/2016

Background:

Tetracyclines enter the bacterial cell wall through passive diffusion and an active transport system. They bind reversibly to the 30S ribosomal subunit of susceptible organisms, thereby causing inhibition of protein synthesis.

New treatment guideline recommendations:

- None identified

Newly approved drugs:

- None identified

Newly approved formulations:

- None identified

Newly approved generics:

- Approved 05/23/2016: Doryx (doxycycline hyclate) 50 mg delayed release tablet; currently available.

Discontinued drugs:

- None identified

FDA Safety Alerts/black box warnings:

- None identified

Pipeline alerts:

Agents pending FDA approval include:

- None identified

References:

1. May DB. Tetracyclines. Hooper DC, Mitty J. (Ed), UpToDate. Waltham MA. Accessed May 2017.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2016. URL: <http://www.clinicalpharmacology-ip.com/>. Updated April 2016.
3. Food and Drug Administration. [WWW.FDA.GOV](http://www.fda.gov). Accessed May 2017.
4. Envolve Pharmacy Solutions internal pipeline database. Accessed May 2017.